Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant

By sjmartinez • September 1, 2023

Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023 Aug 31;25(1):103. doi: 10.1186/s13058-023-01701-9. PMID: 37653397; PMCID: PMC10469877.

Tags: Advanced breast cancer, CDK4/6 inhibitor, First line, Hematology/Oncology, overall survival, Publications, ribociclib

Related Posts

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike[...]

Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)

Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. Real world outcomes of patients[...]

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study

Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski[...]